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Abstract
Purpose Resistant dextrin (RD) supplementation has been shown to alter satiety, glycaemia, and body weight, in overweight 
Chinese men; however, there are limited data on its effects in other demographic groups. Here, we investigated the effects 
of RD on satiety in healthy adults living in the United Kingdom.
Methods 20 normal weight and 16 overweight adults completed this randomised controlled cross-over study. Either RD 
(14 g/day  NUTRIOSE® FB06) or maltodextrin control was consumed in mid-morning and mid-afternoon preload beverages 
over a 28-day treatment period with crossover after a 28-day washout. During 10-h study visits (on days 1, 14, and 28 of each 
treatment period), satietogenic, glycaemic and anorectic hormonal responses to provided meals were assessed.
Results Chronic supplementation with RD was associated with higher fasted satiety scores at day 14 (P = 0.006) and day 28 
(P = 0.040), compared to control. RD also increased satiety after the mid-morning intervention drink, but it was associated 
with a reduction in post-meal satiety following both the lunch and evening meals (P < 0.01). The glycaemic response to the 
mid-morning intervention drink (0–30 min) was attenuated following RD supplementation (P < 0.01). Whilst not a primary 
endpoint we also observed lower systolic blood pressure at day 14 (P = 0.035) and 28 (P = 0.030), compared to day 1, fol-
lowing RD supplementation in the normal weight group. Energy intake and anthropometrics were unaffected.
Conclusions RD supplementation modified satiety and glycaemic responses in this cohort, further studies are required to 
determine longer-term effects on body weight control and metabolic markers.
Clinicaltrials.gov registration CT02041975 (22/01/2014)
Keywords Resistant dextrin · Prebiotic · Satiety · Appetite · Glycaemia · Obesity
Abbreviations
RD  Resistant dextrin
RCT  Randomised controlled trial
S1-S7  Time segments
NDC  Non-digestible carbohydrate
UK  United Kingdom
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Introduction
The relationship between diet, the gut microbiota and aetiol-
ogy of obesity and metabolic disease is complex [1]. Sac-
charolytic fermentation of non-digestible carbohydrates 
(NDC) by the gut microbiota produces short-chain fatty 
acids (SCFA) [2] that can bind to free fatty acid receptors 
and stimulate the release of anorectic hormones [3]. There 
is, therefore, interest in establishing whether increasing die-
tary intake of NDC, with foods or supplements, modifies 
satiety responses, and whether when sustained over a period 
of weeks or months, high intakes of NDC can decrease body 
weight and metabolic disease risk [4, 5].
Resistant dextrin (RD), a NDC and candidate prebiotic, 
has been shown to increase the abundance of bacteroides 
but decrease clostridia in stools from human participants, 
and importantly, to increase the production of SCFA in both 
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animal and in vitro models [6–8]. In separate 9-week and 
12-week dietary intervention studies, RD increased satiety in 
overweight Chinese men [9], suppressed daily energy intake 
and reduced body weight [9, 10]. Moreover, Li et al. [11] 
reported reduced plasma glucose, glycosylated haemoglobin 
and albumin, lower insulin and an improved homeostatic 
model assessment of insulin resistance score in an over-
weight cohort. Elsewhere chronic supplementation with RD 
improved markers of insulin resistance and inflammation in 
women with type 2 diabetes [12].
Risk of metabolic disease typically begins at a lower body 
weight in Asian populations than it does for those of Euro-
pean ancestry [13]. Accordingly, the aim of present study 
was to investigate the effects of RD supplementation on sati-
ety, ad libitum energy intake, glycaemia, anthropometrics 
and blood pressure, in normal and overweight adults in the 
United Kingdom. Here, we describe and discuss findings 
from a randomised controlled trial (RCT) with a 28-day RD 
supplementation period with perceptions of satiety over 




The study was approved by the University of Reading Eth-
ics Committee (11/08), carried out in accordance with the 
Declarations of Helsinki (2008), and registered as a Clinical 
Trial (NCT02041975). The study was a double-blind, ran-
domised controlled trial, with a cross-over design involving 
two 28-day treatment periods, consisting of RD or control 
supplementation, separated by a 28-day washout. Partici-
pants attended a familiarisation visit 14 days before the first 
treatment period and attended study visits on day 1, 14 and 
28 of each treatment period during which the satietogenic 
responses to provided meals over the course of a 10-h study 
day were assessed.
Participants
Healthy adults, classified as normal weight or overweight 
according to accepted BMI classifications [14], were 
recruited from Berkshire, UK and surrounding areas. 
Informed written consent was sought from all participants. 
Inclusion criteria were: aged 22–55 years, normal weight 
(BMI of 22.0–24.9  kg/m2; Asian ethnicity (Chinese or 
Indian ancestry) 20.0—22.9 kg/m2) or overweight (BMI of 
25.0–29.9 kg/m2; Asian ethnicity 23–26.9 kg/m2), resting 
blood pressure (< 160/90 mmHg), fasted blood haemoglobin 
(> 115 g/l females, > 125 g/l males), gamma GT (< 80 IU/l), 
cholesterol (< 6.5 mmol/l), triglycerides (< 1.5 mmol/l) and 
glucose (< 5.5 mmol/l), non-smoking, weight stable and not 
looking to lose or gain weight at the time of taking part 
in the study, cognitive restraint as determined by a three-
factor eating questionnaire [15] ≥ 13 and habitual sleep dura-
tion > 5 h per night, no known cardiovascular, metabolic or 
gastrointestinal disease, not pregnant, free from medication 
(with the exception of contraceptives), no history of drug or 
alcohol misuse, dietary fibre < 30 g/day (to ensure that with 
supplement intake, dietary fibre intakes remained less than 
two SDs above the mean intake in the UK), no antibiotics in 
the last 6 months, no recent or planned blood donations, not 
currently using dietary supplements or no willingness to stop 
their usage for at least 4 weeks prior to, and for the duration 
of, the study. Participants on the study were reimbursed for 
their time and expenses. A sample size of 36 was selected 
based on the findings of Flint et al. [17] who demonstrated 
that using a study power of 0.8, a difference of 10 mm on 
fasting, and 5 mm on mean 4.5 h satiety ratings, can be 
detected with 18 subjects in a paired study design. We, 
therefore, aimed for 18 overweight and 18 normal weight 
participants.
Treatments
Isocaloric orange juice treatment and control beverages 
were developed containing an equal quantity of orange 
juice flavouring. The treatment beverages contained 7 g 
200  ml−1 of resistant dextrin  (NUTRIOSE® FB06, Roquette, 
France) (2 kcal  g−1), whilst the control drink contained 3.5 g 
200  ml−1 of maltodextrin (Glucidex) (4 kcal  g−1). NUTRI-
OSE® FB06 is a non-viscous RD obtained from wheat with 
a fibre content of 85% and a mono- and disaccharide content 
of ≤ 0.5%. Viscosity was similar between both products.
Participants were randomised to treatments with stratifi-
cation for BMI, gender, age and ethnicity using an Excel-
based software package. Investigators and participants were 
blinded to the treatment arms. Participants were asked to 
consume 200 ml servings of the study drinks at 10:30 and 
15:00 each day totalling 14 g  day−1 RD, or 7 g  day−1 of the 
energy-matched maltodextrin control.  (GLUCIDEX®21, 
Roquette, France) (see Table 1 for nutritional information).
Compliance to the dietary intervention, and the effect of 
the intervention on habitual self-reported food intake were 
assessed using weighed food diaries; these were completed 
on the day prior to each of the study visits and at day 7 and 
day 21 of each arm of the intervention.
Clinic study visits
Participants were asked to avoid strenuous exercise and alco-
hol the day before each study visit. Participants consumed 
a standardised macaroni cheese ready meal as the evening 
meal the day before each study visit. Males consumed a 
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500 g meal and females a 400 g meal to reflect gender dif-
ferences in daily energy intake [16]. Participants arrived for 
their study visits at 07:45 in a > 12 h fasted state. Fasted 
body weight and composition measurements were performed 
after urination and with the subject wearing a disposable 
gown using a Tanita bioelectrical impedance meter (Tanita 
‘BC 418ma’ Analyser, Tanita Inc, USA). Blood pressure was 
measured, in triplicate, with the subject in supine position 
(Omron M6 Comfort Monitor, Omron Healthcare, Japan).
Satiety and ad libitum energy intake
Perceived appetite was measured using 100 mm VAS at 
time points shown in Fig. 1 to determine ‘satiety’, ‘hunger’, 
‘fullness’, ‘desire-to-eat’ and ‘prospective food consump-
tion’ (PFC) [17]. Appetite VAS questions were anchored at 
‘Not at all’ and ‘Extremely’. Participants consumed a gen-
der-specific breakfast, equivalent to 10% of male or female 
recommended daily energy intakes, as used previously 
(18), at 08:45. Lunch and evening meals were consumed 
150 min after the mid-morning and mid-afternoon ‘preload’ 
treatment. The lunch meal was a pasta in a tomato sauce, 
with olive oil and parmesan, and was served ad libitum as 
described previously [18]. The evening meal of cheese and 
tomato pizza was also provided ad libitum, with pre-weighed 
servings provided at 5-min intervals. A VAS questionnaire 
on palatability and enjoyment was completed exactly 15 min 
after the start of each study meal and preload.
Biological sample collection
A qualif ied healthcare professional inser ted a 
0.85 mm × 25 mm 23G cannula (Brunz Healthcare, UK) into 
a vein of the participants’ antecubital fossa at 08:00 and this 
remained in situ until the last blood sample at 17:00. Blood 
samples were collected at each study visit at the times shown 
in Fig. 1. At each time point, 5 ml of venous blood was 
transferred into a pre-cooled EDTA tube containing 50 μl 
Inhibitor cocktail (containing DPP-IV, AEBSF and protease 
cocktail; Merck Millipore, UK) and then stored immediately 
on ice. Another 3.5 ml of venous blood was transferred into 
a serum separating tube and kept at room temperature for 
30 min to coagulate. All blood samples were centrifuged 
for 10 min at 1000g before separation of plasma/serum and 
storage at − 80 °C.
Biological sample analyses
Glucose was analysed using an Instrument Laboratory ILAB 
600 auto-analyser (Instrumentation Laboratory Ltd, UK) in 
serum samples collected at day 1, 14 and 28. Manufacturers’ 
low and high control standards were used in all batches. Gut 
Table 1  Nutritional information of the RD and control drink
Resistant Dextrin drink Control drink
RD (7.0 g  NUTRIOSE® FB06, Roquette) and orange juice powder  (Clic®, 
Nestlé) mixed with water
Maltodextrin (3.5 g GLUCIDEX®21, Roquette) and orange juice 
powder  (Clic®, Nestlé) mixed with water
Volume 200 ml Volume 200 ml
Energy 95.9 kcal Energy 95.9 kcal
Protein 0 g Protein 0 g
Carbohydrate 22.2 g Carbohydrate 23.8 g
Sugars 20.4 g Sugars 20.7 g
Fat  < 0.1 g Fat  < 0.1 g
Fibre 6 g Fibre 0 g
Fig. 1  Schematic overview of the study visits. Participants arrived 
at 07:45 and finished at 18:00. Preloads were provided at 10:30 and 
15:00. Standard breakfast, and ad  libitum lunch and evening meals 
were provided at 08:45, 13:00 and 17:30, respectively. Blood samples 
were collected, VAS questionnaires were completed, and water was 
provided at the time points shown. For analytical purposes, the study 
day was divided into time segments (S1–S7)
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hormone concentrations were determined in duplicate using 
Luminex 200 Technology (Bio-Plex, Bio-Rad, Nazareth, 
Belgium) and MILLIPLEX MAP Human Metabolic Hor-
mone Magnetic Bead Panel (Millipore, UK) from samples 
collected at day 1 and 28. The assay was ran as an 8-plex for 
simultaneous quantification of ghrelin (active), GIP (Total), 
GLP-1 (Active), insulin, leptin, PYY (Total), interleukin-6 
(IL-6) and tumour necrosis factor-α (TNF-α). Blood metabo-
lites were analysed in the morning blood samples (collected 
between 07:45 and 13:00), and days 1 and 28, only.
Statistical analysis
All statistical analyses were performed using Predictive 
Analytics Software version 21.0 for Windows (SPSS Inc., 
USA). Statistical significance was accepted at the 5% level. 
The normality of all data was checked using the Shap-
iro–Wilk test and visually by plotting residuals. Data were 
analysed for the entire cohort and for the normal weight 
and overweight sub-groups separately. Correlations between 
appetite measures were determined using the Pearson cor-
relation coefficient. Logged satiety, metabolite, blood pres-
sure and anthropometric data were analysed using a linear 
mixed model with repeated measures. Fixed factors in 
the model were visit (day 1, 14 or 28), treatment (RD or 
control), and the interaction between visit and treatment 
(visit*treatment). Where applicable segment was included as 
a fixed factor. Covariates in the model were treatment order, 
BMI group, gender, and age, however, these were removed 
if their effect on the model was non-significant. Fasting sati-
ety/plasma metabolite data and/or energy consumption at 
lunch or evening meals were used as covariates. Bonfer-
onni correction was used for multiple comparisons. Area 
under the curve (AUC) values were calculated for satiety and 
blood metabolite data using the trapezoid rule. AUC values 
were calculated for key time segments (S): S1, breakfast to 
morning preload (08:45–10:30); S2, after morning preload 
(10:30–11:00); S3, after morning preload (11:00–13:00); S4, 
lunch to afternoon preload (13:00–15:00); S5, post after-
noon preload 1 (15:00–15:30); S6, post afternoon preload 2 
(15:30–17:30); S7, after evening meal (17:30–18:00). Post 
preload AUC values were calculated for the first 30 min, to 
investigate gastric and oro-sensory effects, and from 30 to 
150 min, to investigate post-absorptive effects [19].
Results
Eighty-one adults were screened for the study, 47 met the 
inclusion criteria and were recruited. Eleven participants 
dropped out due to illness, work commitments and medica-
tion use; however, this was not associated with RD or con-
trol supplementation. Of the 36 participants who completed 
the study, 20 were normal weight and 16 were overweight 
(see Table 2). Of the 36 participants, 32 (89%) classed 
themselves as either White-British, White-Irish, or White-
European ethnicity, 1 (3%) as Black ethnicity, and 3 (8%) as 
Asian or Mixed-Asian ethnicity.
Anthropometric, blood pressure and food diary data
Baseline anthropometric and blood pressure data are shown 
in Table 2. Bodyweight, body fat, waist circumference, hip 
circumference, and diastolic blood pressure were unaffected 
by RD or control supplementation. When evaluated across 
the entire cohort, mean systolic blood pressure was unaltered 
by RD supplementation. In a sub-analysis by BMI classifi-
cation, systolic blood pressure was lower at day 28 (mean 
112 mmHg) than days 1 (mean 120 mmHg, P < 0.030) and 
14 (mean 118 mmHg, P = 0.035) in normal weight partici-
pants consuming RD (Fig. 2). No differences in systolic 
blood pressure were found after RD supplementation in 
Table 2  Participant baseline measures
Data presented as means ± SD (range)
Normal weight Overweight
(n = 20) (n = 16)
Male (n = 9) Female (n = 11) Male (n = 8) Female (n = 8)
Age (y) 30.8 ± 9.7 (22–50) 31.7 ± 9.0 (22–46) 37.9 ± 9.0 (26–52) 38.0 ± 12.0 (22–55)
Bmi (kg/m2) 23.3 ± 1.4 (21.0–24.8) 22.5 ± 1.2 (20.3–24.2) 26.6 ± 1.7 (25.2–29.4) 27.2 ± 0.8 (26.1–28.4)
Body Fat (%) 15.7 ± 4.0 (12.1–23.6) 29.4 ± 3.5 (23.9–35.8) 20.9 ± 5.2 (15.1–29.0) 37.0 ± 2.6 (33.7–41.2)
Waist (cm) 82.2 ± 7.1 (77–100) 74.5 ± 5.1 (65–82) 93.7 ± 9.1 (80–112) 83.9 ± 8.1 (74–97)
Hip (cm) 97.1 ± 3.5 (94–103) 97.9 ± 4.4 (87–104) 104.3 ± 4.8 (97–112) 106.0 ± 3.0 (103–111)
Systolic blood pressure (mmHg) 126.8 ± 7.6 (114.0–136.3) 109.3 ± 19.1 (66.3–126.3) 125.5 ± 6.2 (117.0–133.0) 130.8 ± 19.3 (105.0–160.3)
Diastolic blood pressure 
(mmHg)
70.8 ± 5.9 (58.7–77.7) 70.7 ± 10.0 (45.3–82.7) 74.5 ± 8.0 (63.3–90.0) 77.4 ± 12.0 (63.0–102.0)
Fasted blood glucose (mmol/l) 4.5 ± 0.3 (4.1–4.9) 4.5 ± 0.2 (4.1–4.8) 4.5 ± 0.3 (4.3–5.0) 4.2 ± 0.4 (3.8–4.9)
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overweight participants. Neither treatment altered dietary 
intake at home (assessed using weighed food diaries).
Satiety ratings
Fasting
As shown in Fig.  3 and detailed in Supplementary 
tables 1–3, fasting satiety scores were significantly higher 
at day 14 (P = 0.006) and day 28 (P = 0.040), but not day 
1, with RD consumption relative to control. Fasting satiety 
was higher at day 28 compared to day 1 following RD sup-
plementation both when considered across the entire cohort 
and in the normal weight group (P = 0.012), but not for the 
overweight group.
Postprandial
Postprandial desire-to-eat, hunger and prospective food 
consumption (all positively correlated, r = 0.874, P < 0.01) 
were unaffected by RD supplementation. Postprandial sati-
ety was positively correlated to fullness (r 0.841, P < 0.01). 
Supplementary tables 1, 2 and 3 provide AUC satiety data 
for S1–S7 for all participants, normal weight participants 
and overweight participants, respectively. For S1, breakfast 
to morning preload (08:45–10:30), and S2, after morn-
ing preload (10:30–11:00), no treatment or time effects 
were found for AUC satiety in the entire cohort, or in a 
sub-analysis by BMI category. For S3, after the morning 
preload (11:00–13:00) corresponding to the post-breakfast-
absorptive phase, the AUC for satiety was higher for RD 
than for control at day 28 (P = 0.008). This difference was 
found in normal weight participants (P = 0.003) but was not 
observed in overweight participants. For S4, lunch to after-
noon preload (13:00–15:00), AUC satiety was significantly 
lower with RD relative to control at day 28 (P = 0.004), and 
lower at day 28 compared to day 1 (P = 0.019) and day 14 
(P = 0.008). In a sub-analysis, the same differences were 
found in normal weight participants (P < 0.01) but not in 
overweight participants. For S5, post afternoon preload 1 
Fig. 2  Systolic blood pressure in normal weight and overweight par-
ticipants following RD and control treatments. #Systolic blood pres-
sure lower at day 28 compared to day 1 (P = 0.030) in normal weight 
participants following RD treatment. ≠ Systolic blood pressure lower 
at day 28 compared to day 14 (P = 0.035) in normal weight partici-
pants following RD treatment. Data presented as estimated marginal 
means ± 95% confidence interval (CI)
Fig. 3  Fasting satiety and AUC satiety for S3 and S4 in the entire 
cohort. Fasting graph: *Satiety scores higher with RD compared to 
control at day 14 (P = 0.006) and day 28 (P = 0.040). AUC satiety 
S3: * AUC satiety higher with RD compared to control at day 28 
(P = 0.008). AUC satiety S4: * AUC satiety lower with RD relative 
to control at day 28 (P = 0.004). ≠ AUC satiety lower at day 28 com-
pared to day 1 following RD supplementation (P = 0.008). # AUC 
satiety lower at day 28 compared to day 14 following RD supplemen-
tation (P = 0.019). Data presented as estimated marginal means ± 95% 
CI
 European Journal of Nutrition
1 3
(15:00–15:30), no treatment or time effects were found in 
the AUC for satiety across the cohort; however, a significant 
difference between treatments at day 28 was found in normal 
weight (P = 0.020) but not in overweight participants. For 
S6, post afternoon preload 2 (15:30–17:30), no treatment or 
time effects were found for AUC satiety across the cohort, 
or in a sub-analysis by BMI category. For S7, after even-
ing meal (17:30–18:00), AUC satiety was lower with RD 
compared to control at day 28 (P = 0.013) and AUC satiety 
was lower at day 28 compared to day 1 following RD supple-
mentation (P = 0.024). Differences were found in the normal 
weight group but not the overweight group.
Blood metabolites
Fasting
Fasting concentrations of glucose, ghrelin (active), GIP 
(Total), insulin, leptin and tumour necrosis factor-α (TNF-
α) are detailed in Supplementary tables 1–3. Fasting glucose 
concentrations were unaltered by RD or control supplemen-
tation in the entire cohort and normal weight or overweight 
groups. At day 28, fasting GLP-1 levels were significantly 
higher following RD compared to control in the entire 
cohort (P < 0.017) and normal weight group (P < 0.007); 
however, no differences were found between day 1 and day 
28, suggesting a participant and not a treatment effect. At 
day 1 (prior to treatment initiation), mean fasting ghrelin 
was 119.1 in the control arm versus 133.9 in the RD arm 
(P < 0.05).
Postprandial
AUC data for S2 and S3 for blood metabolites are provided 
in supplementary tables 1, 2 and 3. As shown in Fig. 4, post-
prandial AUC glucose in S2 was lower with RD compared 
to control at day 28 (P = 0.044) in the entire cohort. Moreo-
ver, following RD, mean AUC was lower at days 14 and 
28, compared to day 1 (P < 0.01). These differences were 
not found in the overweight group; however in the normal 
weight group, AUC glucose was lower with RD compared 
to control at day 28 (P = 0.037). AUC GIP for S2 was also 
lower at day 28 for RD compared to control in the entire 
cohort (P = 0.002) and normal weight (P = 0.004), but not 
overweight, group. Postprandial insulin, TNF-α, GLP-1, and 
ghrelin responses for S2 were unaltered by RD supplementa-
tion in the entire cohort and BMI groups. AUC responses 
for S3, after morning preload (11:00–13:00), for all blood 
metabolites were unaffected by RD or control in the entire 
cohort. AUC GIP was lower following RD compared to con-
trol at day 28 in the normal weight group (P = 0.011), but 
not the entire cohort or overweight group. Graphs show-
ing glucose and GIP time-point data are presented as sup-
plementary information (Supplementary Figs. 1 and 2). 
Interleukin-6 (IL-6) and PYY data were not analysed due to 
unacceptably high CVs.
Energy intake
On day 1, the ad libitum energy intake at lunch was higher 
following the RD mid-morning preload compared to the 
control drink (mean difference 88 kcal, P = 0.028); Supple-
mentary tables 1,2 and 3. This difference was observed in 
the overweight group (mean difference 170 kcal, (P < 0.001) 
but not in the normal weight group (mean difference 23 kcal, 
P = 0.718). No other treatment nor time effects were 
observed for ad libitum energy intake at the lunch or even-
ing meals. Mean ratings of enjoyment, taste and palatability 
of all the study meals and preload drinks were all > 65 (out 
of 100) and did not differ significantly between treatments 
or visits.
Fig. 4  AUC glucose and GIP responses to the morning preload drink 
in S2 in the entire cohort. * AUC glucose lower with RD than control 
treatment at day 14 (P = 0.044) and day 28 (P = 0.009), ≠ AUC glu-
cose lower at day 28 compared to day 1 following RD supplementa-
tion (P = 0.009) and AUC glucose lower at day 14 compared to day 1 
following RD treatment (P = 0.009). AUC GIP lower with RD com-
pared to control at day 28 (P = 0.002). Data presented as estimated 
marginal means ± 95% CI
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Study compliance
No significant differences in self-reported study compliance 
were found between treatments, with 98% ± 5% (mean ± SD) 
compliance for control and 98% ± 4% (mean ± SD) compli-
ance reported for RD treatments.
Discussion
RD supplementation has been shown to alter indices of sati-
ety, glycaemic control, and bodyweight in overweight males 
in China [9–12], yet there are limited data on the effects 
of RD consumption on related parameters in other demo-
graphic groups, including Western populations. Accord-
ingly, the current study looked to address this knowledge 
gap. Specifically, we investigated the effects of chronic RD 
consumption on satiety over the course of in-clinic con-
trolled study visits, in both normal weight and overweight 
adults living in the UK.
Chronic consumption of RD was compared against an 
energy-matched maltodextrin control. Habitual diet was 
unaffected by the intervention, and therefore treatment with 
the supplementary RD represents a significant increase in 
fermentable fibre intake over and above control. RD con-
sumption was associated with increased fasting satiety rat-
ings on study visits at day 14 and day 28 of the chronic 
intervention. In previous work, using an in vitro gut fermen-
tation model, we have shown that RD fermentation elicits 
increases in short-chain fatty acid concentrations [8]. Of the 
short-chain fatty acids, propionate in particular is of interest 
due to its potential anorectic activities [20]; indeed, recent 
intervention studies have demonstrated that targeted delivery 
of propionate to the colon in a prebiotic can suppress appe-
tite [21]. We speculate that the chronic supplementation of 
this fermentable fibre may have increased SCFA production 
in the gut and, thus, modified perceptions of fasted satiety 
in our participants. In contrast to previous studies [11, 12], 
we did not find that either fasting glucose or fasting insulin 
concentrations were affected by RD supplementation; how-
ever, this might be a consequence of our experimental design 
with a low/normal fasting glucose level used as an inclusion 
criteria for the study.
RD was also associated with a higher perceived satiety 
score in the run up to lunch (S3). During the study visits, 
participants consumed RD, or maltodextrin control, in a 
drink in the mid-morning period. Postprandial glucose and 
GIP, an incretin and important marker of nutrient absorp-
tion [22], in S2 were lower following the RD drink com-
pared to the control at day 28. The fact that the glycaemic 
response was significantly lower at days 14 and 28 compared 
to day 1 suggests that this was a chronic effect of RD sup-
plementation; however, it could also be due to the higher 
immediate bioavailability of digested sugar from the malto-
dextrin. Thus, it is possible that the control drink induced 
a nutrient spike in S2 and a slump in S3, although this was 
not observed in the metabolite data. This must be consid-
ered, alongside higher potential intestinal SCFA production, 
associated perhaps with RD consumed the previous day, 
as a potential mechanistic explanation for the higher self-
reported feelings of satiety with the RD in the period prior to 
lunch. This nutrient bioavailaibility hypothesis is consistent 
with previous acute intervention studies with dietary fibres 
[23]. It is worth noting that repeated high postprandial glu-
cose responses are associated with progression of diabetes 
mellitus and cardiovascular diseases due to unfavourable 
effects on oxidative stress, beta cell function and nutrient 
transporters [24].
Two and a half hours after the mid-morning preload, the 
participants consumed lunch; this was followed by a two-
hour window until the mid-afternoon preload and then a 
further two and half hours until the evening meal. At day 
28, the RD was associated with reduced satiety post- both 
the lunch and evening meals relative to control. There was 
no difference in calorie intake at either meal to explain 
this. Unfortunately, blood metabolite data from the morn-
ing, including appetite related hormones, did not provide 
a possible explanation for these responses. The morning 
preload will not have reached the colon by lunch but may 
well have arrived in the caecum by the time of the evening 
meal; in vitro batch culture fermentation of prebiotics sug-
gests that their utilisation in the gut takes place over many 
hours [25]. It is plausible that the concentration of circulat-
ing short-chain fatty acids is high following the overnight 
fast because the microbiota were still utilising the previous 
days RD, and that the SCFA concentrations began to decline, 
due to substrate depletion, through the study day. Further, 
the more immediate availability of energy from the malto-
dextrin control in the morning and afternoon preloads may 
have had carry-over effects on nutrient processing following 
the lunch and evening meals.
In a sub-analysis by BMI category, we noted that the 
effects of RD supplementation on satiety were found exclu-
sively amongst the normal weight adults. Previous research 
has shown that the satiety response correlates with the 
dose of RD consumed [9]. The 14 g/day RD provided in 
the current study may have been insufficient to alter satiety 
responses in the overweight adults. There is also evidence 
that the microbial community of individuals with a high 
body weight might have a different capacity for the utili-
sation of non-digestible carbohydrate [26]. Future studies 
should explore the differential production of short-chain 
fatty acids in response to prebiotics in body weight associ-
ated enterotypes.
Whilst not an a priori defined endpoint for this study, we 
noted that RD consumption was associated with a clinically 
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meaningful reduction in systolic blood pressure, albeit only 
in the normal weight participants. This observation has not 
previously been reported for RD but it is a purported benefit 
of other NDC [27], and even small reductions in systolic 
blood pressure are associated with reduced risk of coronary 
heart disease, coronary artery disease and stroke [28]; future 
intervention studies should evaluate this further.
Limitations to the current study: First, whilst the energy 
content of the drinks were matched, total carbohydrate and 
sugar content of the RD and control drinks were margin-
ally different (Table 1). Nonetheless, glycaemic responses 
to RD and control morning preloads were comparable at 
the start of the treatment periods (day 1). Second, the length 
of the treatment period (28 days) may have been too short 
to observe any anthropometric changes. We only observed 
statistically significant responses to the intervention in our 
normal weight participants; there were, however, more of 
these (n = 20), than the overweight participants (n = 16). It 
may be important to include a larger sample of overweight 
participants in follow up work.
In conclusion, this study provides evidence that chronic 
consumption of RD reduces postprandial glycaemia and 
influences fasted satiety in healthy adults living in the UK. 
Intervention studies of a greater duration are needed to 
determine whether RD consumption can help regulate body 
weight and influence metabolic health. From a mechanis-
tic perspective studies of the differential impact of RD on 
the microbiota of normal and overweight individuals might 
help to explain our findings. Finally, the observed potential 
anti-hypertensive properties of RD are of interest but require 
further investigation.
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